We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+48.19%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$439M
AUM Growth
-$62.6M
Cap. Flow
-$159M
Cap. Flow %
-36.16%
Top 10 Hldgs %
66.42%
Holding
69
New
13
Increased
8
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$37.3M
2
MDT icon
Medtronic
MDT
+$17.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$12M
4
PFE icon
Pfizer
PFE
+$9.04M
5
KVUE icon
Kenvue
KVUE
+$5.41M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$20.4M
2
THC icon
Tenet Healthcare
THC
+$18.7M
3
DXCM icon
DexCom
DXCM
+$18.4M
4
HNGE
Hinge Health
HNGE
+$16.7M
5
BSX icon
Boston Scientific
BSX
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Consumer Staples 0.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.71B
$126M 28.7%
3,204,184
+1,461,282
+84% +$37.3M
CGON icon
2
CG Oncology
CGON
$6.34B
$64.5M 14.68%
1,600,899
+100,957
+7% +$2.94M
MDT icon
3
Medtronic
MDT
$109B
$18.2M 4.13%
+190,600
New +$17.5M
BSX icon
4
Boston Scientific
BSX
$68.6B
$16M 3.65%
164,300
-157,500
-49% -$16.3M
ORKA
5
Oruka Therapeutics
ORKA
$5.45B
$12.7M 2.89%
660,424
+308,300
+88% +$4.57M
BMY icon
6
Bristol-Myers Squibb
BMY
$128B
$11.6M 2.64%
+257,600
New +$12M
NTRA icon
7
Natera
NTRA
$37.1B
$11.3M 2.58%
70,400
-128,900
-65% -$20.4M
DHR icon
8
Danaher
DHR
$137B
$10.8M 2.47%
54,700
-35,000
-39% -$6.96M
TEVA icon
9
Teva Pharmaceuticals
TEVA
$36.2B
$10.3M 2.34%
510,000
-179,500
-26% -$3.15M
CATX icon
10
Perspective Therapeutics
CATX
$333M
$10.3M 2.34%
2,994,033
+1,135,437
+61% +$4.14M
JBIO
11
Jade Biosciences
JBIO
$1.24B
$9.73M 2.21%
1,127,186
– –
PFE icon
12
Pfizer
PFE
$141B
$9.34M 2.12%
+366,400
New +$9.04M
TMO icon
13
Thermo Fisher Scientific
TMO
$209B
$9.17M 2.09%
18,900
-10,700
-36% -$4.98M
CNTX icon
14
Context Therapeutics
CNTX
$57.5M
$8.7M 1.98%
8,981,855
+1,504,600
+20% +$1.22M
GMAB icon
15
Genmab
GMAB
$17.8B
$7.61M 1.73%
248,100
-401,900
-62% -$9.79M
MTSR
16
DELISTED
Metsera Inc
MTSR
$7.35M 1.67%
+140,500
New +$5.19M
UNH icon
17
UnitedHealth
UNH
$380B
$6.15M 1.4%
17,800
-14,200
-44% -$4.29M
ARVN icon
18
Arvinas
ARVN
$535M
$5.95M 1.35%
698,363
+455,201
+187% +$3.45M
COR icon
19
Cencora
COR
$60.7B
$5.94M 1.35%
19,000
-13,800
-42% -$4.06M
EHC icon
20
Encompass Health
EHC
$11.4B
$5.32M 1.21%
41,900
-32,100
-43% -$3.82M
JNJ icon
21
Johnson & Johnson
JNJ
$647B
$4.97M 1.13%
+26,800
New +$4.59M
CI icon
22
Cigna
CI
$77.1B
$4.78M 1.09%
+16,600
New +$4.91M
ABBV icon
23
AbbVie
ABBV
$458B
$4.58M 1.04%
+19,800
New +$4.03M
MCK icon
24
McKesson
MCK
$99.9B
$4.48M 1.02%
5,800
-7,700
-57% -$5.42M
CARL
25
Carlsmed
CARL
$312M
$4.31M 0.98%
+321,912
New +$4.4M
1
2 3

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2025 Portfolio in Review

As of Q3 2025, Avidity Partners Management held 69 positions worth $439M, down 12% from $502M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avidity Partners Management withdrew a net $159M in Q3 2025, closing 26 positions and reducing 20 holdings. Its most notable exit was Tenet Healthcare, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Consumer Staples.

Against the trend, Avidity Partners Management opened a new position in Medtronic worth $18.2M.

  • Avidity Partners Management's largest Q3 2025 buy was Medtronic: 190,600 shares worth $18.2M.
  • Avidity Partners Management added most to Dianthus Therapeutics in Q3 2025, an estimated $37.3M increase.
  • Avidity Partners Management's biggest Q3 2025 reduction was Natera, cutting an estimated $20.4M.
  • Avidity Partners Management fully exited Tenet Healthcare in Q3 2025, selling an estimated $18.7M.
  • Avidity Partners Management's ten largest holdings make up 66% of its $439M portfolio in Q3 2025.
  • Avidity Partners Management opened 13 new positions and closed 26 in Q3 2025.
  • Avidity Partners Management's portfolio value fell 12% quarter-over-quarter to $439M.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.